Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Notified -
Globe Newswire24-02-2025, 13:00
Hummingbird Bioscience Licenses Novel Antibodies to Immunome 7-01-2025, 20:00
